Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for.
Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024
Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline
Robust.
The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.
PureTech Health plc – Half-Year Report streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.